Nuclear stand-off could hurt Iran's cancer patients

Updated - November 28, 2021 09:39 pm IST

Published - November 18, 2010 10:09 pm IST - AP

The human impact from the wrangling between Iran and the West over its nuclear programme could fall first in nuclear medicine clinics around the country, where hundreds of cancer patients a week get treatment with radioactive isotopes.

Iran says fuel for the Tehran research reactor that produces the isotopes will run out in September next year, leaving it without the materials needed to diagnose and treat some 8,50,000 cancer patients across the country.

A deal for the West to provide fuel for the reactor has all but fallen apart in the deadlock over Iran's broader nuclear programme, and Iran's drive to produce the fuel on its own has brought condemnation from the U.S. and Europe. They fear the programme could boost what they contend is the secret goal of Iran's nuclear ambitions to produce a bomb.

Iran denies the claim, saying its programme is only for peaceful purposes and has touted the need for medical isotopes to justify its programme.

Negotiators from Iran and the United States and its allies are expected to meet soon, likely later this month or early next, in their first direct nuclear talks in more than a year. A deal to provide Iran with fuel for the research reactor may be on the agenda, but U.S. officials have already expressed pessimism that one can be reached.

The Tehran reactor is fuelled by rods made from uranium that has been enriched to a level of 20 per cent. It has been running on fuel rods that Iran imported from Argentina more than a decade ago to produce medical isotopes like iodine-131, used to treat thyroid cancer.

Isotope import

Iran imports some ready-made isotopes, but it has faced greater restrictions under U.N. sanctions and has to pay higher prices to get them. Sanctions do not directly ban the sale to Iran of medical equipment, but they make foreign producers more reluctant to provide it, and those who will sell it do so at inflated prices.

Uranium enrichment lies at the heart of Iran's dispute with the West. Low-enriched uranium, at around 3.5 per cent, can be used to fuel a reactor to generate electricity, which Iran says is the intention of its programme. But if uranium is further enriched to around 90 per cent purity, it can be used to develop a nuclear warhead.

U.N. fear

Iran has been producing low-enriched uranium for several years, but the United Nations has demanded that it stop enrichment for fear it will be increased to weapons-grade. The U.N. has imposed four rounds of financial sanctions on Iran for refusing the demands.

Last year, the United States proposed a U.N.-backed deal that it hoped would provide a confidence building measure and leave Iran at least temporarily unable to produce a bomb. It proposed that Iran ship abroad most of its stocks of low-enriched uranium, which would be further purified to 20 per cent and turned into fuel rods, which would then be sent back to Iran to power the Tehran medical reactor. Doing so would leave Tehran's stocks too low to produce enough high-enriched uranium for a bomb.

But Iran balked, arguing that the deal did not provide enough guarantees the West would follow through with the fuel rods. It proposed modifications that the West rejected.

This year, Iran reached a separate deal with Turkey and Brazil to ship 2,640 pounds (1,200 kg) of low-enriched uranium abroad in return for fuel rods. But since Iran had been continuing to produce low-enriched uranium in the meantime, the deal would still have left it enough in theory to build a bomb, so the West rejected the agreement.

At the same time, Iran began in February to further enrich uranium to 20 per cent, aiming to produce fuel for the Tehran reactor on its own. But it still has to turn the material into fuel rods. Iran says it has the capability to do so, but Western nuclear experts are sceptical.

Iran's nuclear chief, Ali Akbar Salehi, said Iran would be able to fuel the reactor on its own by next September, when the imported fuel is due to run out.

The American ambassador to the U.N. nuclear watchdog, Glyn Davies, said the original fuel swap deal was “picture perfect” to ensure the Tehran reactor keeps running and producing isotopes. He said in March that after Iran's rejection “we can only assume they're enriching the material for other purposes.”

U.S. officials have said Washington could agree to a new version of the fuel swap deal, but it would have to entail Iran shipping a larger amount of low-enriched uranium abroad and stopping its 20 per cent enrichment. The Americans are sceptical Iran would agree, though Iranian officials have signalled they might halt the further enrichment if fuel rods are guaranteed.

Iran has 120 nuclear medicine centres around the country, with some 200 patients a week getting iodine-131 treatments for thyroid cancer, according to Mohammad Ghannadi, a top nuclear official.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.